Overview
Fragment 176-191 is the C-terminal tail of the human growth hormone molecule — the 15 amino acids responsible for its fat-burning effects, isolated from everything else. The idea was elegant: keep the lipolysis, drop the growth promotion, insulin resistance and water retention.
It is popular in the grey market for cutting phases, but the honest evidence base is thin.
How It Works
The 176-191 region of GH was identified in research mapping which parts of the molecule drive fat metabolism. The fragment appears to stimulate lipolysis and inhibit lipogenesis — fat release and fat storage — without binding the full GH receptor or raising IGF-1.
The evidence gap
Most supporting data comes from rodent studies and older research on a related compound (AOD-9604), which failed to show convincing efficacy in human obesity trials. The peptide community uses it anyway, but expectations should be calibrated accordingly.
Key Benefits
Fat loss support — the entire point of the molecule; animal data is positive, human data is weak.
No IGF-1 elevation — avoids the growth-promoting effects of full GH, at least in theory.
No blood sugar disruption — unlike GH, it does not appear to impair glucose tolerance.
Cutting-phase popularity — widely stacked with fasted cardio in community protocols.
Side Effects & Considerations
Reported side effects are mild: injection site irritation and occasional flushing or fatigue. The bigger issue is efficacy uncertainty — the closest pharmaceutical relative failed human trials, and no quality human data exists for the fragment itself.
Verdict
If fat loss is the goal, the GLP-1 class has overwhelming human evidence and this does not. Fragment 176-191 persists on reputation and hope more than data. Not approved for human use, WADA prohibited, and grey-market quality applies as always.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Community protocol (anecdotal) | 250-500 mcg | 1-2 times daily, fasted | 4-8 weeks | Typically injected before fasted morning cardio. No human dose-ranging studies exist. |
Warnings
Weak human evidence — closest relative failed clinical trials. Not approved for human use. WADA prohibited.